Clinical Trial

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-12-09; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2022-03-16
Trial Details
NCT Number NCT05168930
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: BeiGene
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Enrollment 45 participants
Start Date 2022-02-18
Primary Completion 2026-10-28 (estimated)
Study Completion 2028-10-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-05